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Abstract
Enterococci are reportedly the third most common group of endocarditis-causing pathogens but data on enterococcal infective endocarditis
(IE) are limited. The aim of this study was to analyse the characteristics and prognostic factors of enterococcal IE within the International
Collaboration on Endocarditis. In this multicentre, prospective observational cohort study of 4974 adults with deﬁnite IE recorded from June
2000 to September 2006, 500 patients had enterococcal IE. Their characteristics were described and compared with those of oral and group D
streptococcal IE. Prognostic factors for enterococcal IE were analysed using multivariable Cox regression models. The patients’ mean age was
65 years and 361/500weremale. Twenty-three per cent (117/500) of cases were healthcare related. Enterococcal IE weremore frequent than
oral and groupD streptococcal IE in North America. The 1-year mortality rate was 28.9% (144/500). E. faecalis accounted for 90% (453/500) of
enterococcal IE. Resistance to vancomycin was observed in 12 strains, eight of which were observed in North America, where they accounted
for 10% (8/79) of enterococcal strains, and was more frequent in E. faecium than in E. faecalis (3/16 vs. 7/364 , p 0.01). Variables signiﬁcantly
associated with 1-year mortality were heart failure (HR 2.4, 95% CI 1.7—3.5, p <0.0001), stroke (HR 1.9, 95% CI 1.3—2.8, p 0.001) and age
(HR 1.02 per 1-year increment, 95% CI 1.01—1.04, p 0.002). Surgery was not associated with better outcome. Enterococci are an important
cause of IE, with a high mortality rate. Healthcare association and vancomycin resistance are common in particular in North America.
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Introduction
Enterococci are reportedly the third most common group of
endocarditis-causing pathogens after streptococci and
staphylococci. A few, relatively small, case series of entero-
coccal infective endocarditis (IE) have been published [1–9].
Based on these studies, the most distinctive features of
enterococcal IE are that they more frequently affect elderly
and prosthetic valve patients [3,5,8], and are more often
nosocomially acquired than other forms of IE [2,7]. Nosocomial
acquisition appears to worsen outcome. The mortality rate is
intermediate to that of streptococcal and staphylococcal IE
[1,2,4,8]. Patients with prosthetic valve enterococcal IE are
more likely to develop intracardiac abscesses and less likely to
have detectable vegetations on echocardiography than patients
with native valve enterococcal IE [3]. In contrast, native and
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prosthetic valve enterococcal IE do not appear to differ in rate
of complications, need for surgery or mortality [1].
To date, all but two [4,6] of these case series were collected
retrospectively and some are more than 20 years old [9]. The
aim of this study was to analyse the current characteristics and
prognostic factors of enterococcal IE within the International
Collaboration on Endocarditis – Prospective Cohort Study
(ICE-PCS), which forms the largest series of IE ever collected
prospectively.
Methods
International Collaboration on Endocarditis – Prospective
Cohort Study
Data from the ICE-PCS were used for this study. The
background and inclusion criteria of this prospective, multi-
centre, international registry of IE have been reported
previously [10,11]. Between June 2000 and September 2006,
4794 patients from 64 centres in 28 countries were enrolled.
The ICE-PCS database is maintained at the Duke Clinical
Research Institute, the coordinating centre for ICE studies.
Informed consent (oral/written) was obtained from all patients
according to local institutional review boards or ethics
committee guidelines at all sites.
Patient selection and data collection
Patients were identiﬁed prospectively using site-speciﬁc pro-
cedures to ensure consecutive enrollment. Patients were
enrolled in the ICE-PCS if they met criteria for possible or
deﬁnite IE based on the modiﬁed Duke criteria [12]. Only
patients with deﬁnite IE were included in the current study. To
preserve the assumption of independence of observations,
only the ﬁrst episode of IE recorded for an individual patient
was used in the analysis.
The method of data collection for the ICE-PCS has been
previously reported [11]. Brieﬂy, all sites used a standard case
report form to collect data. It included 275 variables and was
developed by the ICE according to standard deﬁnitions. Data
were collected during the index hospitalization and then
entered at the coordinating centre or by site investigators
using an Internet-based data entry system. Microbial species
identiﬁcations were performed locally in each medical centre
according to its own procedures. All sites obtained informa-
tion on 1-year survival through the civil registry ofﬁce, medical
records and/or patient contact when necessary.
Deﬁnitions and case groups
Deﬁnitions of the variables included in the ICE-PCS case
report form have been previously reported [11].
Community-acquired IE was deﬁned as IE diagnosed at
the admission time (or within the ﬁrst 48 h) in a patient
who did not fulﬁll the criteria for healthcare-associated
infection. Healthcare-associated IE was deﬁned as nosoco-
mial IE or non-nosocomial healthcare-associated IE. Noso-
comial IE was deﬁned as IE that developed in a patient who
was hospitalized for more than 48 h before the onset of
signs or symptoms consistent with IE. Non-nosocomial
healthcare-associated IE was deﬁned as IE diagnosed within
48 h of admission in an outpatient with extensive healthcare
contact, as reﬂected by any of the following criteria: (i)
receipt of intravenous therapy, wound care or specialized
nursing care at home within the 30 days before the onset of
IE; (ii) attendance at a hospital or haemodialysis clinic or
receipt of intravenous chemotherapy within the 30 days
before the onset of IE; (iii) hospitalization in an acute care
hospital for 2 or more days in the 90 days before the onset
of IE; or (iv) residence in a nursing home or long-term care
facility.
In an effort to group centres with geographical and
sociodemographic similarities, ﬁve meta-regions were deﬁned
as follows: North America, South America, Northern Europe,
Southern Europe/Middle East/Africa and Australia/New
Zealand/Asia (see supporting data).
The group of enterococcal IE included all cases of IE due to
E. faecalis, E. faecium, E. durans, E. avium, E. casseliﬂavus or
E. gallinarum, as well as enterococci that could not be further
identiﬁed to the species level. For comparative analyses, we
formed two additional groups of IE, oral streptococci IE and
group D streptococci IE. Table 1 shows the list of organisms
that are included in these two groups. We did this because
enterococci, oral and group D streptococci all belong to the
Streptococcaceae family.
TABLE 1. List of pathogens included in the three groups of
pathogens used for comparative analysis
Enterococci N Oral streptococci N
Group D
streptococci N
E. faecalis 453 S. mitis 79 S. bovisa 270
E. faecium 19 S. mutans 64 S. gallolyticus 17
E. durans 6 S. oralis 42 S. equinus 2
E. casseliﬂavus 2 S. sanguis 31 S. pasteurianus 1
E. gallinarum 1 S. salivarius 23 Group D NISb 3
Enterococci NISb 19 S. gordonii 12
S. anginosus 17
S. constellatus 5
S. intermedius 5
S. milleri group NISb 4
S. acidominimus 7
S. parasanguis 1
S. viridans NISb 533
TOTAL 500 823 293
a‘S. bovis’ refers to the results of species identiﬁcation according to the former,
outdated classiﬁcation of group D streptococci.
bNot identiﬁed to species level.
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Statistical analysis
Data are presented as mean (SD) for continuous variables and
as percentages for categorical variables. Simple comparisons
were made using Kruskal–Wallis, chi-squared or Fisher exact
tests as appropriate.
Multivariable Cox regression analysis was used to identify
factors associated with in-hospital mortality. The endpoint was
the status (dead vs. alive) 1 year after discharge from hospital.
The following variables were evaluated for their potential
impact on prognosis: age, sex, ICE meta-regions, Charlson
index, diabetes mellitus, cancer, haemodialysis, valve prosthesis
before IE, nosocomial acquisition, heart failure (deﬁned by
NYHA class 3 or 4), stroke, development of at least one
paravalvular complication, and cardiac surgery. The latter
variable was assigned a time-dependent format, as recom-
mended for assessing the impact of cardiac surgery on
outcome [13]. For multivariable analysis, variables entered
into the model were those with a p-value  0.05 in bivariable
analysis. A stepwise variable selection was then performed,
with an enter p-value of 0.05 and a remove p-value of 0.05.
Two age- and sex-adjusted models were built up: one within
the group of enterococcal IE to identify prognostic factors
associated with this condition and one across the three pooled
groups to assess the impact of enterococci vs. oral strepto-
cocci and vs. group D streptococci on IE prognosis.
For all tests, statistical signiﬁcance was determined at the
0.05 level. All statistical analyses were performed using SAS
software (version 9.2, SAS Institute, Cary, NC, USA).
Results
A total of 1616 patients with deﬁnite streptococcal or
enterococcal IE were identiﬁed according to the selection
criteria (Fig. 1). There were 500 cases of enterococcal IE
(30.9%), 823 cases of oral streptococcal IE (51.0%) and 293
cases of group D streptococcal IE (18.1%). The distribution of
species is shown in Table 1.
Of the 500 patients with enterococcal IE, 361 (72.6%) were
male. The patients’ mean age was 65.5 (15.3) years. The
proportion of healthcare-associated IE was 117/500 (23.4%)
(65/500 nosocomial and 52/500 non-nosocomial). Patients
undergoing chronic haemodialysis accounted for 41/500
(8.4%). IE developed on native valves in 324/488 (66.4%)
patients and on prosthetic valves in 142/488 (29.1%) patients.
In the remaining 34 patients, the location of IE was either
extravalvular or unknown. In terms of clinical manifestations,
the only signiﬁcant difference between E. faecalis and E. fae-
cium IE consisted of a higher incidence of stroke in E. faecalis IE
(16% vs. 0%, p 0.05). Two hundred and nine of the 497
patients (42.1%) underwent valve surgery during the initial
hospital stay. Patients with prosthetic valve IE were less often
operated on than patients with native valve IE (49/142 vs. 151/
321, p 0.012). Non-operated patients were older than oper-
ated ones (68.5 vs. 62 years, p <0.001).
The 1-year mortality rate was 144/498 (28.9%), and higher
in prosthetic valve IE than in native valve IE (55/142 vs. 80/322,
p 0.002). The 1-year mortality rate did not differ between
operated and non-operated patients in the overall enterococ-
cal IE (56/219 vs. 88/278, p 0.14). Nor did it differ in native
(32/144 vs. 48/177, p 0.3) or prosthetic (17/46 vs. 38/96,
p 0.76) valve IE subgroups.
Overall, resistance to ampicillin and vancomycin was
observed in 18 and 12 enterococcal strains, respectively.
Seven of the 11 vancomycin-resistant strains were isolated
from nosocomially-acquired IE, whereas this was the case for
only 49/386 (13%) vancomycin-susceptible strains (p 0.004)
(the place of acquisition was unknown or missing in one case
of vancomycin-resistant IE and in 17 cases of vancomy-
cin-susceptible IE). Eight of the 12 vancomycin-resistant
strains (66.7%) were observed in North America, where they
accounted for 10% of enterococcal strains. In contrast, no
vancomycin resistance was observed in South Africa and
Australia/New Zealand and the percentages of vancomycin
resistance were only 1.0% (1/105 strains) in Northern
Europe and 2.7% (3/111 strains) in Southern Europe/Middle
East/Africa. The overall rate of high-level resistance to
aminoglycoside was 111/290 (38%). It was lower in North
America (12/54, 22%) than in the other four meta-regions
(p 0.0002).
In addition, resistance to ampicillin and resistance to
vancomycin were observed more often in E. faecium than in
E. faecalis strains (9/16 vs. 8/404, p <0.0001 and 3/16 vs. 7/364,
p 0.01, respectively). Resistance to aminoglycoside was not
different between the two species. The 1-year mortality rate
was higher in vancomycin-resistant than in vancomycin-sus-
ceptible enterococcal IE (7/12 vs. 110/384, p 0.03). Patients
treated with an aminoglycoside-containing regimen presentedFIG. 1. Patients’ selection ﬂow-chart.
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a lower 1-year mortality rate than patients treated without
aminoglycoside (57/218 vs. 29/68, p 0.01).
The comparative characteristics of enterococcal, oral
streptococcal and group D streptococcal IE are summarized
in Fig. 2 and Table 2. Enterococcal IE were more common
than oral and group D streptococcal IE in North America,
where they accounted for 50.3% of the cases when pooling the
three groups. In all four other meta-regions, the ranking was
more conventional, with oral streptococci, enterococci and
group D streptococci occurring in descending order (Fig. 2).
Comparison of the three organism groups demonstrated the
following characteristics of enterococcal IE. Enterococcal IE
more often developed in relation to healthcare intervention
and in elderly patients with co-morbid conditions, as exhibited
by a higher proportion of patients with diabetes or receiving
haemodialysis and by a higher Charlson index. Patients with
enterococcal IE more often had a prior history of IE, a
prosthetic valve or an implanted intracardiac device. The
course of the disease did not differ signiﬁcantly in terms of
frequency and type of complications, although the time
between ﬁrst symptoms and admission was signiﬁcantly
shorter in enterococcal IE, which may reﬂect a more
aggressive course of the disease and/or a more rapid diagnosis
of healthcare-associated cases. The 1-year mortality rate was
signiﬁcantly higher for enterococcal than for streptococcal IE
(Table 2).
The variables that were analysed as potential prognostic
factors for enterococcal IE are listed in Table 3. After
bivariable analysis, six variables were then selected for the
age- and sex-adjusted multivariable model. Finally, three
variables were identiﬁed as signiﬁcantly and independently
associated with 1-year mortality. These were heart failure
(HR 2.43 vs. no heart failure, 95% CI 1.71—3.45, p <0.0001),
stroke (HR 1.90 time-dependent, 95% CI 1.28—2.82, p 0.001)
and age (HR 1.02 per 1-year increment, 95% CI 1.01—1.04, p
0.002). Valve surgery, as a time-dependent variable, had no
impact on prognosis. The same analyses were redone on the
subgroup of E. faecalis IE and led to essentially the same results
(i.e. the same prognostic factors were identiﬁed and associated
with similar HRs (data not shown)).
In order to assess the role of enterococci as a potential
prognostic factor, we built a multivariable model based on the
pooled 1616 cases of IE. This model identiﬁed the same
prognostic factors as in the previous step and three additional
factors: diabetes, presence of a prosthetic valve before IE, and
causative microorganism. The model thus demonstrated a
signiﬁcantly lower risk of death for oral streptococcal IE (HR
0.62, 95% CI 0.45—0.87) and group D streptococcal IE (HR
0.65, 95% CI 0.50–0.85), as compared with enterococcal IE
(Table 4).
Discussion
This study conﬁrms that E. faecalis accounts for about 90% of
enterococcal IE, as previously reported [3]. Overall, entero-
coccal IE forms the third most important group of IE after
streptococcal and staphylococcal IE. Interestingly, in this study,
enterococcal IE was more frequent than both oral and group
D streptococcal IE in North America, which may be related to
the higher proportion of healthcare-associated IE in this part of
the world [14], a hypothesis supported by the signiﬁcantly
higher rate of resistance to ampicillin and vancomycin for
enterococci in North America as compared with the rest of
the world. The present study also conﬁrms that enterococcal
IE is less often community acquired or involving native valves
than previously reported. We actually found that among
enterococcal IE, almost 25% were healthcare-associated IE,
especially nosocomial, and 30% were prosthetic valve IE. In
addition, enterococcal IE mainly affects elderly and debilitated
patients. Interestingly, this newer proﬁle was not associated
with a higher rate of complications compared with oral or
group D streptococcal IE. The in-hospital mortality rate of
enterococcal IE, although signiﬁcantly higher than in strepto-
coccal IE despite a shorter delay to diagnosis, remained within
the range of 11–18% observed in previous series [1,2,4]. In
FIG. 2. Percentages of enterococci, oral streptococci and group D
streptococci as the causative agents of IE among the ﬁve ICE
meta-regions.
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terms of prognosis, we failed to identify any factors speciﬁc to
enterococcal IE, whose prognosis was mainly affected by age,
occurrence of stroke and heart failure. However, we found
that Enterococcus as the cause of IE was an adverse indepen-
dent prognostic factor for mortality within the group of IE due
to Streptococcaceae. In addition, after integration into the
model of the 1471 cases of Staphylococcus aureus IE contained
in the ICE-PCS database (data not shown), we found that
Staphylococcus aureus as the cause of IE was associated with a
higher risk of death (HR 1.6, 95% CI 1.3—2), which conﬁrmed
the lower risk of death associated with oral and group D
streptococci.
The major strength of this study is that it assembled the
largest series of prospectively collected cases of enterococcal
IE ever published. Cases were collected recently and rapidly
TABLE 3. Results of prognosis analysis by Cox regression
analysis within the group of enterococcal IE. The multivar-
iable model is adjusted for age and sex. The endpoint is 1-year
mortality
Bivariable
analysis
Multivariable
analysis
HR 95% CI HR 95% CI
Age, per 1-year increment 1.02 1.01–1.03 1.02 1.01–1.04
Sex, male vs. female 0.72 0.49–1.07 – –
Charlson index, per 1-unit increment 1.29 1.11–1.50 – –
Haemodialysis, yes vs. no 1.15 0.65–2.04 – –
Diabetes, yes vs. no 1.37 0.95–1.98 – –
Cancer, yes vs. no 1.62 1.04–2.53 – –
Nosocomial acquisition, yes vs. no 0.86 0.53–1.42 – –
Stroke (time-dependent) 2.00 1.36–2.94 1.90 1.28–2.82
Heart failure, yes vs. no 2.47 1.75–3.50 2.43 1.71–3.45
Paravalvular complications 1.48 1.06–2.06 – –
Surgery (time-dependent) 1.04 0.74–1.46 – –
The variables selected as psoguotic factors are shown in bold.
TABLE 4. Identiﬁcation of prognostic factors by Cox regres-
sion analysis in the pooled three groups of IE. The multivar-
iable model is adjusted for age and sex. The endpoint is 1-year
mortality
Bivariable
analysis
Multivariable
analysis
HR 95% CI HR 95% CI
Age, per 1-year increment 1.03 1.02–1.04 1.02 1.01–1.03
Sex, male vs. female 0.95 0.74–1.22 – –
Charlson index, per 1-unit increment 1.42 1.27–1.57 – –
Haemodialysis, yes vs. no 1.91 1.20–3.03 – –
Diabetes, yes vs. no 1.63 1.25–2.12 1.43 1.09–1.88
Cancer, yes vs. no 1.94 1.44–2.62 – –
Valve prosthesis before IE, yes vs. no 1.82 1.44–2.29 – –
Nosocomial acquisition, yes vs. no 1.52 1.00–2.33 – –
Stroke (time-dependent) 2.31 1.78–2.99 2.23 1.71–2.91
Heart failure, yes vs. no 2.88 2.29–3.63 2.77 2.15–3.57
Paravalvular complications 1.71 1.37–2.14 – –
Surgery (time-dependent) 1.07 0.85–1.35 – –
Causative microorganism
Enterococci 1 – 1 –
Oral streptococci 0.46 0.36–0.58 0.62 0.45–0.87
Group D streptococci 0.54 0.39–0.74 0.65 0.50–0.85
The variables selected as psoguotic factors are shown in bold.
TABLE 2. Main characteristics of enterococcal IE compared with those of oral and group D streptococcal IE
Enterococci
n = 500 30.9%
Oral streptococci
n = 823 51.0%
Group D
streptococci
n = 293 18.1% p value
Age (years), mean [SD] 65.5 (15.3) 54.6 (18.4) 65.2 (12.4) <0.0001
Male sex, N (%) 361 (72.6) 584 (71.0) 218 (74.7) 0.46
History of IE, N (%) 62 (12.5) 86 (10.5) 21 (7.2) 0.07
Admission delay > 1 month, N (%) 172 (36.8) 350 (44.9) 142 (51.4) <0.0001
Haemodialysis, N (%) 41 (8.4) 11 (1.4) 6 (2.1) <0.0001
Diabetes, N (%) 110 (22.4) 90 (11.1) 56 (19.3) <0.0001
Cancer, N (%) 55 (11.2) 67 (8.3) 34 (11.7) 0.11
Charlson index, mean [SD] 1.7 (1.8) 1.0 (1.5) 1.3 (1.5) <0.0001
Place of acquisition, N (%) <0.0001
Community 352 (70.4) 758 (92.1) 280 (95.6)
Healthcare, nosocomial 65 (13.0) 12 (1.5) 3 (1.0)
Healthcare, non-nosocomial 52 (10.4) 25 (3.0) 4 (1.4)
Multiple, unknown, missing 31 (6.2) 28 (3.4) 6 (2.0)
Intracardiac device, N (%) 61 (12.4) 31 (3.8) 21 (7.2) <0.0001
Type of IE, N (%) <0.0001
Native valve 324 (66.4) 641 (80.9) 216 (75.8)
Prosthetic valve 142 (29.1) 130 (16.4) 62 (21.8)
Other 22 (4.5) 21 (2.7) 7 (2.5)
Location of vegetation, N (%) 0.18
Left-sided only 380 (80.3) 643 (83.0) 241 (87.6)
Right-sided only 26 (5.5) 27 (3.5) 6 (2.2)
Left + right 11 (2.3) 14 (1.8) 4 (1.5)
Elsewhere 16 (3.4) 18 (2.3) 4 (1.5)
No vegetation 40 (8.5) 73 (9.4) 20 (7.3)
Missing information 27 (5.4) 48 (5.8) 18 (6.1)
Stroke, N (%) 78 (16.0) 118 (14.7) 38 (13.3) 0.59
Embolic event, N (%) 94 (19.3) 147 (18.3) 70 (24.4) 0.08
Heart failure, N (%) 94 (18.8) 139 (16.9) 56 (19.1) 0.90
Intracardiac abscess, N (%) 57 (11.8) 110 (13.6) 33 (11.5) 0.51
Paravalvular complications in prosthetic valve IE, N (%) 53 (10.8) 41 (5.1) 15 (5.2) 0.0002
Valve surgery within 60 days, N (%) 209 (42.1) 380 (46.5) 137 (47.2) 0.22
One-year mortality, N (%) 144 (28.9) 120 (14.6) 52 (17.8) <0.0001
IE, infective endocarditis.
Percentages are based on the missing data.
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(the ﬁrst 6 years of the 21st century), providing an accurate
view of the current proﬁle of this disease.
A limitation of our study is the fact that case collection was
tertiary care centre-based and not population-based. This may
have introduced a referral bias towards a selection of more
severe cases than the ‘average’. However, in a large prospec-
tive population-based study of IE conducted recently, where
enterococcal IE represented 10.5% (n = 52) of the 497 cases
of IE collected, enterococcal IE was the third most frequent
group of IE, occurred more frequently in patients with
prosthetic valves, and was more prone to be nosocomially
acquired than oral or group D streptococcal IE [15]. Therefore
we can reasonably assume that this ICE-PCS series is
representative of enterococcal IE in clinical practice. Another
limitation is the fact that the impact of the antibiotic regimens
on prognosis could not be analysed because the ICE-PCS
database contains few details about the treatment: overall
planned duration and predominant antibiotics used. Further-
more, this information was missing in about half of the study
population, which could bias results. Finally, bacteriological
identiﬁcation techniques were not standardized because each
centre used its own procedures. This explains the high rate of
‘viridans’ streptococci.
Enterococcal infection is an increasingly important cause of
IE with a high mortality rate. Those affected include the elderly
and patients with prosthetic valves or intracardiac devices.
Healthcare association is common, in particular in North
America, where emerging resistance to vancomycin is a matter
of concern.
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